Thus, our results support the conclusion that GDF15 should be considered as a possible therapeutic co-target to eradicate or prevent the development of DTP cells during treatment with eribulin in both TNBC and luminal breast cancer subtypes. This evidence concerns the gene GDF15 and breast carcinoma.